Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab vs Lenalidomide Maintenance Therapy for Multiple Myeloma (NUTRIVENTION-4)
NCT04497961Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2020
- Primary completion
- Aug 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, lenalidomide in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2020; status: active, not recruiting.
02
Drugs
daratumumablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04497961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497961.